Next Article in Journal
A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting
Previous Article in Journal
p53 Isoforms and Their Implications in Cancer
Previous Article in Special Issue
Micelles Structure Development as a Strategy to Improve Smart Cancer Therapy
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessArticle

miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy

Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(9), 289; https://doi.org/10.3390/cancers10090289
Received: 17 July 2018 / Revised: 7 August 2018 / Accepted: 21 August 2018 / Published: 25 August 2018
(This article belongs to the Special Issue Nanotechnology and Cancer)
  |  
PDF [5881 KB, uploaded 25 August 2018]
  |  

Abstract

The therapeutic application of microRNA(s) in the field of cancer has generated significant attention in research. Previous studies have shown that miR-205 negatively regulates prostate cancer cell proliferation, metastasis, and drug resistance. However, the delivery of miR-205 is an unmet clinical need. Thus, the development of a viable nanoparticle platform to deliver miR-205 is highly sought. A novel magnetic nanoparticle (MNP)-based nanoplatform composed of an iron oxide core with poly(ethyleneimine)-poly(ethylene glycol) layer(s) was developed. An optimized nanoplatform composition was confirmed by examining the binding profiles of MNPs with miR-205 using agarose gel and fluorescence methods. The novel formulation was applied to prostate cancer cells for evaluating cellular uptake, miR-205 delivery, and anticancer, antimetastasis, and chemosensitization potentials against docetaxel treatment. The improved uptake and efficacy of formulations were studied with confocal imaging, flow cytometry, proliferation, clonogenicity, Western blot, q-RT-PCR, and chemosensitization assays. Our findings demonstrated that the miR-205 nanoplatform induces significant apoptosis and enhancing chemotherapeutic effects in prostate cancer cells. Overall, these study results provide a strong proof-of-concept for a novel nonviral-based nanoparticle protocol for effective microRNA delivery to prostate cancer cells. View Full-Text
Keywords: miR-205; docetaxel; prostate cancer; chemosensitivity and EMT miR-205; docetaxel; prostate cancer; chemosensitivity and EMT
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary materials

  • Supplementary File 1:

    PDF-Document (PDF, 1409 KB)

  • Externally hosted supplementary file 1
    Doi: NA
    Link: http://NA
    Description: No
SciFeed

Share & Cite This Article

MDPI and ACS Style

Nagesh, P.K.B.; Chowdhury, P.; Hatami, E.; Boya, V.K.N.; Kashyap, V.K.; Khan, S.; Hafeez, B.B.; Chauhan, S.C.; Jaggi, M.; Yallapu, M.M. miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy. Cancers 2018, 10, 289.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top